Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Atezolizumab + Obinutuzumab in Richter Transformation of CLL
2024-516675-32-00Phase 2Completed
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, atezolizumab and obinutuzumab in Richter's syndrome (RS), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and diffuse large B-cell lymphoma (DLBCL), sponsored by ASST Grande Ospedale Metropolitano Niguarda. Primary endpoint: Overall Response Rate at End of Cycle 6. Started Nov 2024; status: completed.
02
Drugs
venetoclaxatezolizumabobinutuzumab
03
Conditions
Richter's syndrome (RS)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2024-516675-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516675-32-00.